Pfizer and BioNTech may know before rivals  about Covid vaccine shot        

Companies plan first look after 32 coronavirus infections in massive 44-000-person trial

Pfizer has given itself four chances to get a preliminary result on its Covid-19 vaccine. Picture: Scott Eisen/Bloomberg

The Covid-19 vaccine trial designed by Pfizer and its German partner BioNTech may allow them to find whether their shot works before their fastest moving rivals.

The companies plan a first look after a mere 32 coronavirus infections have accumulated in their 44,000-person trial.